Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2005 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00006100
First received: August 3, 2000
Last updated: December 17, 2013
Last verified: May 2005

August 3, 2000
December 17, 2013
April 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00006100 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
A Phase I Pilot Trial to Evaluate the Toxicity of Epstein-Barr Virus Specific T-Lymphocytes or Peripheral Blood Mononuclear Cells for the Treatment of Relapsed/Refractory Hodgkin's Disease

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Donor white blood cells that are treated in the laboratory with Epstein-Barr virus may be effective treatment for Hodgkin's lymphoma.

PURPOSE: Phase I trial to study the effectiveness of allogeneic Epstein-Barr virus-specific cytotoxic T cells in treating patients who have progressive, relapsed, or refractory Hodgkin's lymphoma.

OBJECTIVES:

  • Determine the toxicity of allogeneic Epstein Barr virus (EBV)-specific cytotoxic T-lymphocytes (EBV CTL) in patients with progressive, relapsed, or refractory EBV-positive Hodgkin's lymphoma.
  • Detect alterations in the anti-EBV cellular immunity of patients treated with EBV CTL.

OUTLINE: Donors undergo leukapheresis. Epstein Barr virus-specific cytotoxic T lymphocytes (EBV CTL) are cultured in vitro.

Patients receive an infusion of EBV CTL over 10 minutes on day 0. The EBV CTL infusion is preceded by 3 doses of fludarabine. Patients then receive interleukin-2 injections for 12 days after the EBV CTL infusion.

Patients are followed weekly for 1.5 months, twice a month for 1.5 months, and then monthly for 3 months.

PROJECTED ACCRUAL: A total of 9 patients will be accrued for this study.

Interventional
Phase 1
Primary Purpose: Treatment
Lymphoma
  • Biological: aldesleukin
  • Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
  • Drug: fludarabine phosphate
  • Procedure: peripheral blood stem cell transplantation
Not Provided
Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004 May 1;100(9):1892-901.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically proven Hodgkin's lymphoma

    • Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation
    • Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER)
  • Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria:

    • EBV seropositive
    • HIV negative
    • HTLV-1 negative
    • Hepatitis B surface antigen and hepatitis B core antibody IgM negative
    • Hepatitis C antibody negative
    • Must share at least 1 HLA haplotype with donor

PATIENT CHARACTERISTICS:

Age:

  • 18 to 75

Performance status:

  • Not specified

Life expectancy:

  • At least 8 weeks

Hematopoietic:

  • Not specified

Hepatic:

  • Bilirubin less than 2.0 mg/dL
  • SGOT/SGPT less than 2.5 times normal (unless liver metastases are present)

    • If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required
  • No hepatic dysfunction causing moribundity

Renal:

  • Creatinine clearance greater than 50 mL/min
  • No renal dysfunction causing moribundity

Cardiovascular:

  • No cardiac dysfunction causing moribundity

Pulmonary:

  • No pulmonary dysfunction causing moribundity

Other:

  • No neurologic dysfunction causing moribundity
  • No history of severe transfusion reactions with blood products (including fetal calf serum)
  • Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Disease Characteristics

Chemotherapy:

  • See Disease Characteristics
  • No concurrent antimetabolites

Endocrine therapy:

  • Not specified

Radiotherapy:

  • See Disease Characteristics

Surgery:

  • Not specified
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00006100
CDR0000068109, PSCI-2003-257, UAB-0002, NCI-G00-1829
Not Provided
Not Provided
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
Study Chair: Kenneth G. Lucas, MD Milton S. Hershey Medical Center
National Cancer Institute (NCI)
May 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP